SMAD4 and neoplasm: A comparison of SMAD4 mutations with clinical cancer data did not show an association of mutations with tumor staging but showed an association with decreased overall survival (OS) at the pan-cancer level (log-rank test: P = 0.049 and P = 0.0006 for hotspot and deleterious mutations, respectively) (Figure 4G).